12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Deals

Rigel, AstraZeneca deal

Rigel granted AstraZeneca exclusive, worldwide rights to develop and commercialize inhaled Janus kinase (JAK) inhibitor R256. The compound is in preclinical testing to...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >